This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
4 Big Drugmaker Stocks to Watch Out For as Recovery Gains Steam
by Kinjel Shah
Most Large Cap Pharmaceuticals industry players' Q2 results were strong. Regulatory/pipeline updates related to COVID-19 medicines/vaccines continue to take center stage. JNJ, RHHBY, PFE and AZN are worth retaining in your portfolio.
Takeda (TAK) Hematology Candidate Fails in Late-Stage Study
by Zacks Equity Research
Takeda's (TAK) pipeline candidate, pevonedistat, fails to achieve statistically significant event-free survival in patients with hematological disorders.
Pharma Stock Roundup: New Warning Order by FDA for JAK Drugs, & Pipeline Updates
by Kinjel Shah
FDA requires a heart-risk warning on the label of JAK inhibitor medicines, Pfizer's (PFE) Xeljanz, Lilly's (LLY) Olumiant, and AbbVie's (ABBV) Rinvoq. Sanofi, Merck and others give pipeline updates.
AC Immune's (ACIU) Stock Up Despite Mixed Data From AD Study
by Zacks Equity Research
AC Immune's (ACIU) candidate for mild-to-moderate AD meets one of the two co-primary endpoints. Resultantly, the stock price rises 16%
Roche (RHHBY) Withdraws Tecentriq for Breast Cancer in the U.S.
by Zacks Equity Research
Roche (RHHBY) will withdraw Tecentriq for treating adults with unresectable locally advanced or metastatic triple-negative breast cancer in the United States.
Global Blood (GBT) Thrives on Oxbryta, Overdependence a Woe
by Zacks Equity Research
Global Blood's (GBT) Oxbryta is approved for treating sickle cell disease. The drug has seen solid uptake since its launch. However, sole dependence on Oxbryta for growth remains a concern.
Bio-Path (BPTH) to Begin Clinical Study on Leukemia Drug
by Zacks Equity Research
Bio-Path Holdings' (BPTH) IND application for BP1002 receives clearance from the FDA. It is set to begin a phase I/Ib study for treating AML patients. The stock rises following the announcement.
Regeneron (REGN) COVID-19 Antibody Cocktail Gets CMA in the UK
by Zacks Equity Research
Regeneron (REGN) gets Conditional Marketing Authorization for its antibody cocktail, casirivimab and imdevimab for COVID-19 infection in the United Kingdom.
Coherus (CHRS), Junshi Announce Positive NSCLC Study Results
by Zacks Equity Research
Coherus BioSciences (CHRS) and partner Junshi announce positive data from a late-stage study on toripalimab for the first-line treatment of NSCLC.
OPKO Health's (OPK) Arm Boosts Prenatal Screening With Buyout
by Zacks Equity Research
OPKO Health's (OPK) BioReference's acquisition to expand its NIPS offerings and thereby enhance prenatal screening.
Epizyme's (EPZM) Q2 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
Epizyme (EPZM) reports wider-than-expected loss for the second quarter of 2021 despite its revenues beating estimates. As a result, stock price declines.
Halozyme (HALO) Beats on Q2 Earnings, Raises 2021 Guidance
by Zacks Equity Research
Halozyme (HALO) second-quarter earnings and sales beat estimates. The company raises 2021 guidance. Stock up.
Prothena (PRTA) Q2 Earnings Top Estimates, Pipeline in Focus
by Zacks Equity Research
Prothena's (PRTA) earnings for the second quarter of 2021 beat estimates. Its pipeline remains in focus as the company expects to receive milestone payments from partners.
Puma (PBYI) Q2 Loss Narrower Than Expected, Nerlynx View Cut
by Zacks Equity Research
Puma Biotech (PBYI) reports better-than-expected Q2 earnings and sales. It lowers 2021 Nerlynx sales guidance.
Exelixis (EXEL) Beats on Q2 Earnings & Revenues, Ups Sales View
by Zacks Equity Research
Exelixis (EXEL) beats on both earnings and revenues in the second quarter. Both figures increase on a year-over-year basis.
Pharma Stock Roundup: LLY, NVO, BAYRY Q2 Earnings, SNY's TBIO Buyout, FDA Updates
by Kinjel Shah
Lilly (LLY), Novo Nordisk (NVO) and Bayer (BAYRY) announce Q2 results. FDA approves AstraZeneca's (AZN) lupus medicine, Saphnelo. Sanofi (SNY) to buy Translate Bio.
Regeneron (REGN) Q2 Earnings Beat, REGEN-COV Boosts Performance
by Zacks Equity Research
Regeneron (REGN) beats on Q2 earnings while sales record strong year-over-year growth on solid performance of Dupixent and Eylea, and significant contribution from REGEN-COV.
Sarepta (SRPT) Q2 Earnings Beat, 2021 Sales View Raised
by Zacks Equity Research
Strong demand for Sarepta's (SRPT) DMD drugs boosts its top line in Q2. The company also raises revenues guidance for the year. It plans to start a pivotal study on SRP-9001 next month. Stock up.
Jazz Pharma (JAZZ) Q2 Earnings Beat, Sales Ride on GW Buyout
by Zacks Equity Research
Jazz Pharma's (JAZZ) product revenues grow in the second quarter on the back of strong demand for its new drugs and additional sales from drugs added with the acquisition of GW Pharmaceuticals.
Amgen (AMGN) Q2 Earnings Top, COVID-Led Sales Woes to Linger
by Zacks Equity Research
Amgen (AMGN) beats Q2 estimates for both earnings and sales. It expects the pandemic to continue to hurt sales growth in the second half of 2021.
ImmunoGen (IMGN) Q2 Loss Narrower Than Expected, Revenues Lag
by Zacks Equity Research
ImmunoGen (IMGN) reports narrower-than-expected loss but misses revenue estimates.
Seagen (SGEN) Q2 Earnings Beat Estimates, Revenues Surge Y/Y
by Zacks Equity Research
Seagen (SGEN) reports narrower-than-expected loss for the second quarter of 2021 while revenues beat estimates.
AbbVie's (ABBV) Q2 Earnings In Line, 2021 Guidance Raised
by Zacks Equity Research
AbbVie (ABBV) matches second-quarter 2021 earnings estimates while beating the same for sales. Sales of new immunology drugs, Skyrizi and Rinvoq, reach $1 billion.
Blueprint Medicines (BPMC) Misses on Q2 Earnings & Revenues
by Zacks Equity Research
Blueprint Medicines (BPMC) misses estimates for revenues and earnings in the second quarter of 2021. Nevertheless, the company provides encouraging pipeline updates.
TEVA Q2 Earnings Beat Estimates, Revenues Miss, Stock Up
by Zacks Equity Research
TEVA beats on second-quarter earnings but misses on sales. The company lowers 2021 sales view. It expects to settle opioid litigation in the coming year.